Novel therapeutic approaches and drug-delivery technologies are improving control of pain and inflammation after cataract and other ocular surgeries.
Two new novel steroids, one insert and one injection, are commercially available to better customize postoperative treatment after cataract and other ocular surgeries.
“These new drug-delivery systems are a major step forward and will both help reduce ocular toxicity and improve patient compliance,” Dr. Epitropoulos said.
A dexamethasone ophthalmic intracanalicular insert, 0.4 mg (Dextenza, Ocular Therapeutix, Inc.) was approved in 2018. This device, which is inserted into the punctum after ophthalmic surgery to treat pain and inflammation, is used instead of topical corticosteroid drops during the postoperative period. The insert delivers a sustained release of dexamethasone over a 30-day period.
Dr. Epitropoulos pointed out that in addition to lessening the treatment burden, it also is preservative free, and prevents exacerbation of ocular surface disease via occlusion of the punctum. It is the only FDA-approved preservative-free steroid on the market today, she said.
Another form of dexamethasone was introduced, in early 2018, i.e., the dexamethasone intraocular suspension 9% (Dexycu, EyePoint Pharmaceuticals Inc.). This treatment, Dr. Epitropoulos noted, is the only FDA-approved sustained-release intracameral injection intended to treat inflammation after ocular surgery. The effect of one injection lasts for 30 days.
Alice Epitropoulos, MD
E: [email protected]
Dr. Epitropoulos is a speaker and/or consultant for Bausch + Lomb, EyePoint Pharmaceuticals, Kala Pharmaceuticals, Ocular Therapeutix, and Omeros.